KaNDy Therapeutics has announced the appointment of Andrew Kay as chairman of the board.
With extensive international board and business experience, both in biotech and at major pharmaceutical companies, Andrew is also chairman of the board at NeRRe Therapeutics and chairman at Blueberry Therapeutics.
Andrew started his industry career in the pharmaceutical sector working in international roles at Novartis, AstraZeneca and Eli Lilly. He was previously the CEO of Algeta, which was sold to Bayer for $2.9 billion in 2014, and was chairman at Wilson Therapeutics. He also gained a BPharm Hons from Nottingham University School of Pharmacy.
Mary Kerr CEO of KaNDy Therapeutics and NeRRe Therapeutics, said: “I am delighted to announce Andrews’s appointment as indepentent Chairman. Andrew has unrivalled experience of working internationally at biotech and pharma companies, including leading multiple successful exits and product launches, which will be invaluable to KaNDy as we progress our product candidate NT-814, which recently entered a Phase 2b trial, towards commercialisation.”
